Abstract
Background
Tumor markers are useful for diagnosis and follow-up. We studied the prognostic value of baseline and serial carcinembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA 19.9) measurements in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods
Sixty-three patients with pseudomyxoma peritonei were treated with cytoreductive surgery and HIPEC. The tumor markers CEA and CA19.9 were collected before therapy and at 3-month intervals during follow-up.
Results
Preoperative CEA and CA19.9 levels were increased in, respectively, 75% and 58% of the patients. Baseline tumor marker values were related to the extent of tumor. Immediately after HIPEC, both tumor markers decreased markedly (P<.0001). CA19.9 was shown to be a more useful tumor marker than CEA for follow-up. During follow-up, a high absolute CA19.9 level (P=.0005) was predictive for imminent recurrence. Patients who never attained a normal CA19.9 level showed a higher recurrence rate at 1 year (53%; SE, 15%), in comparison to patients with did so (6%; SE 4%). The median lead time of increased CA19.9 to recurrence was 9 months.
Conclusions
The measurement of the tumor marker CA19.9 is useful in evaluating therapy in patients with pseudomyxoma peritonei treated with cytoreductive surgery and HIPEC. CA19.9 is a prognostic factor for predicting recurrent disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome.Adv Surg 1996;30:233–80.
Hsieh SY, Chiu CT, Sheen IS, Lin DY, Wu CS, et al. A clinical study on pseudomyxoma peritonei.J Gastroenterol Hepatol 1995;10:86–91.
Landen S, Bertrand C, Maddern GJ, et al. Appendiceal mucoceles and pseudomyxoma peritonei.Surg Gynecol Obstet 1992;175:401–4.
Kuo CM, Kuo CH, Changchien CS, Chiu KW, Hsu TT. Pseudomyxoma peritonei with high serum CA19-9: report of three cases.Changgeng Yi Xue Za Zhi 1999;22:94–9.
Maekawa Y, Nakamura K, Nogami R. A case of dermatomyositis associated with pseudomyxoma peritonei originating from mucinous adenocarcinoma of the appendix.J Dermatol 1992;19:420–3.
Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.Br J Surg 2001;88:458–63.
Molina R, Bonfrer J, Banfi G, et al. External evaluation of LIAISON tumour marker assays on the fully automated chemiluminescent LIAISON immunoassay analyser.Clin Lab 2000;46:169–79.
Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.Stat Med 1984;3:35–44.
Forones NM, Tanaka M. CEA and CA 19-9 as prognostic indexes in colorectal cancer.Hepatogastroenterology 1999;46:905–8.
Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases.Intern Med 1999;38:840–1.
Ueda T, Shimada E, Urakawa T. The clinicopathologic features of serum CA 19-9-positive colorectal cancers.Surg Today 1994;24:518–25.
Plebani M, Giacomini A, Beghi L, et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation.Anticancer Res 1996;16:2249–52.
Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K. Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma.Am J Gastroenterol 1994;89:101–5.
Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19.9 levels in colorectal cancer.Ann Surg 1992;216:55–9.
Kuusela P, Jalanko H, Roberts P, et al. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.Br J Cancer 1984;49:135–9.
Fernandez-Fernandez L, Tejero E, Tieso A. Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9.Eur J Surg Oncol 1995;21:388–90.
Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review.Ann Clin Biochem 1998;35:364–70.
Morales-Gutierrez C, Vegh I, Colina F, et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19,9 determination.Cancer 1999;86:1675–81.
Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.J Surg Oncol 1992;49:78–85.
Lopez JB, Royan GP, Lakhwani MN, Mahadaven M, Timor J. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies.Int J Biol Markers 1999;14:172–7.
Nakayama T, Watanabe M, Teramoto T, Kitajima M. Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients.Anticancer Res 1997;17:1379–82.
Behbehani AI, Al Sayer H, Farghaly M, et al. Prognostic significance of CEA and CA 19-9 in colorectal cancer in Kuwait.Int J Biol Markers 2000;15:51–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Ruth, S., Hart, A.A.M., Bonfrer, J.M.G. et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Annals of Surgical Oncology 9, 961–967 (2002). https://doi.org/10.1007/BF02574513
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02574513